US7696182 — Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
Method of Use · Assigned to ND Partners LLC · Expires 2026-05-16 · 0y expired
What this patent protects
This patent protects a composition used to prevent infection and patency complications in blood catheters, containing taurinamide derivatives, biologically acceptable acids or salts, and a low concentration of heparin.
USPTO Abstract
The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising: (A) at least one taurinamide derivative, (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof; and (C) heparin at a low concentration.
Drugs covered by this patent
- Heparin Sodium In Plastic Container (Heparin Sodium) · Fresenius Kabi
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3774 |
— | Heparin Sodium In Plastic Container |
U-3774 |
— | Heparin Sodium In Plastic Container |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.